XML 59 R46.htm IDEA: XBRL DOCUMENT
v3.25.2

Note 16 - Non-controlling Interests (Tables) | 3 Months Ended
--- | ---
Aug. 31, 2025
Notes Tables |
Condensed Balance Sheet [Table Text Block] |
|  | Aphria |  |  | ColCanna |  |  | August 31, |
|  | Diamond |  |  | S.A.S. |  |  | 2025 |
Current assets |  | $ | 90,684 |  |  | $ | 5 |  |  | $ | 90,689 |
Non-current assets |  |  | 112,250 |  |  |  | 3,485 |  |  |  | 115,735 |
Current liabilities |  |  | (128,471 | ) |  |  | (7,036 | ) |  |  | (135,507 | )
Non-current liabilities |  |  | (31,408 | ) |  |  | (1,442 | ) |  |  | (32,850 | )
Net assets |  | $ | 43,055 |  |  | $ | (4,988 | ) |  | $ | 38,067 |
|  | SH |  |  | CC Pharma |  |  | Aphria |  |  | ColCanna |  |  | May 31, |
|  | Acquisition |  |  | Nordic ApS |  |  | Diamond |  |  | S.A.S. |  |  | 2025 |
Current assets |  | $ | — |  |  | $ | — |  |  | $ | 83,390 |  |  | $ | 20 |  |  | $ | 83,410 |
Non-current assets |  |  | — |  |  |  | — |  |  |  | 114,677 |  |  |  | 3,348 |  |  |  | 118,025 |
Current liabilities |  |  | — |  |  |  | — |  |  |  | (126,986 | ) |  |  | (6,953 | ) |  |  | (133,939 | )
Non-current liabilities |  |  | — |  |  |  | — |  |  |  | (31,720 | ) |  |  | (1,442 | ) |  |  | (33,162 | )
Net assets |  | $ | — |  |  | $ | — |  |  | $ | 39,361 |  |  | $ | (5,027 | ) |  | $ | 34,334 |
Condensed Income Statement [Table Text Block] |
|  | Aphria |  |  | ColCanna |  |  | August 31, |
|  | Diamond |  |  | S.A.S. |  |  | 2025 |
Revenue |  | $ | 18,102 |  |  | $ | — |  |  | $ | 18,102 |
Total expenses |  |  | 13,497 |  |  |  | (186 | ) |  |  | 13,311 |
Net (loss) income |  |  | 4,605 |  |  |  | 186 |  |  |  | 4,791 |
Other comprehensive (loss) income |  |  | (911 | ) |  |  | (147 | ) |  |  | (1,058 | )
Net comprehensive (loss) income |  | $ | 3,694 |  |  | $ | 39 |  |  | $ | 3,733 |
Non-controlling interest % |  |  | 49 | % |  |  | 10 | % |  | NA |
Comprehensive (loss) income attributable to NCI |  |  | 1,810 |  |  |  | 4 |  |  |  | 1,814 |
Net comprehensive (loss) income attributable to NCI |  | $ | 1,810 |  |  | $ | 4 |  |  | $ | 1,814 |
|  | SH |  |  | CC Pharma |  |  | Aphria |  |  | ColCanna |  |  | August 31, |
|  | Acquisition |  |  | Nordic ApS |  |  | Diamond |  |  | S.A.S. |  |  | 2024 |
Revenue |  | $ | — |  |  | $ | — |  |  | $ | 18,558 |  |  | $ | — |  |  | $ | 18,558 |
Total expenses |  |  | — |  |  |  | 5 |  |  |  | 9,216 |  |  |  | 630 |  |  |  | 9,851 |
Net (loss) income |  |  | — |  |  |  | (5 | ) |  |  | 9,342 |  |  |  | (630 | ) |  |  | 8,707 |
Other comprehensive (loss) income |  |  | — |  |  |  | (1 | ) |  |  | 1,041 |  |  |  | 277 |  |  |  | 1,317 |
Net comprehensive (loss) income |  | $ | — |  |  | $ | (6 | ) |  | $ | 10,383 |  |  | $ | (353 | ) |  | $ | 10,024 |
Non-controlling interest % |  |  | 32 | % |  |  | 25 | % |  |  | 49 | % |  |  | 10 | % |  | NA |
Comprehensive (loss) income attributable to NCI |  |  | — |  |  |  | (2 | ) |  |  | 5,088 |  |  |  | (35 | ) |  |  | 5,051 |
Net comprehensive (loss) income attributable to NCI |  | $ | — |  |  | $ | (2 | ) |  | $ | 5,088 |  |  | $ | (35 | ) |  | $ | 5,051 |

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration